We read with great interest the data analysis by Cippà et al. (1) on the associations between in-hospital mortality and drugs taken by the patients with COVID-19 disease for various comorbidities. The method chosen by the authors to examine the effects of drugs led data mainly on renin–angiotensin–aldosterone system inhibitors (RAASI), yet they also discuss other molecules used for several comorbidities, and the resulting messages become clinically very important.

中文翻译：

---

RAASI、非甾体抗炎药、抗糖尿病药和抗凝剂：在 SARS-CoV-2 感染中需要将更多数据标记为有害或中性 [生物科学]

我们非常感兴趣地阅读了 Cippà 等人的数据分析。( 1 ) 关于住院死亡率与 COVID-19 患者因各种合并症服用的药物之间的关系。作者选择的用于检查药物作用的方法主要针对肾素-血管紧张素-醛固酮系统抑制剂 (RAASI) 的数据，但他们也讨论了用于几种合并症的其他分子，由此产生的信息在临床上变得非常重要。